Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avoiding TSE in surgery?

This article was originally published in The Gray Sheet

Executive Summary

A claim for "complete elimination" of transmissible spongiform encephalopathy (TSE) in surgical instruments is not currently possible, but a sponsor could reasonably validate a claim for "reducing TSE infectivity" using animal model studies, the FDA's General Hospital & Personal Use Devices Panel concluded Sept. 27 at a meeting in Gaithersburg, Md. TSE is the source of "mad cow disease" in bovine and the rare but deadly Creutzfeldt-Jakob disease in humans. The device center is anticipating marketing approval applications for products or processes intended to decontaminate surgical tools, although it has not received any such submissions yet...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT022739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel